On the Marketing and Use of Pharmacogenetic Tests for Psychiatric Treatment

JAMA Psychiatry. 2018 Aug 1;75(8):769-770. doi: 10.1001/jamapsychiatry.2018.0834.

Authors

George S Zubenko¹, Barbara R Sommer², Bruce M Cohen^{3

4}

Affiliations

¹ Distinguished Life Fellow, American Psychiatric Association, Washington, DC.
² Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
³ Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
⁴ Program for Neuropsychiatric Research, McLean Hospital, Belmont, Massachusetts.

PMID: 29799933
DOI: 10.1001/jamapsychiatry.2018.0834

No abstract available

MeSH terms

Costs and Cost Analysis
Depressive Disorder, Major* / drug therapy
Depressive Disorder, Major* / genetics
Drug-Related Side Effects and Adverse Reactions / genetics
Genetic Testing* / economics
Genetic Testing* / methods
Humans
Pharmacogenetics / methods*
Psychotropic Drugs / pharmacokinetics*
Reproducibility of Results
Treatment Outcome

Substances

Psychotropic Drugs